← All trials
NCT05426434
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- Feb 28, 2025
- Completion date
- Dec 31, 2025
- First posted
- Jun 22, 2022
- Last posted
- Sep 2, 2022
- Enrollment
- 1172
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Menzies School of Health ResearchLead sponsor
- Curtin UniversityCollaborator
- Menzies School of Health ResearchOverall official - principal investigator
- University of LiverpoolCollaborator
- University of MelbourneCollaborator
- Government of Papua New GuineaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.